ZED1227 not checked
Dr. Falk Pharma GmbH · TAK-227
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “oral treatment with different daily doses of ZED1227 vs placebo”In the company’s words, NCT07298343 on ClinicalTrials.gov
- Tested for
- Celiac Disease
- Main trialPhase 2
- “A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet”In the company’s words, NCT07298343 on ClinicalTrials.gov
- Other names
- TAK-227
Other drugs for Celiac Disease
- Larazotide AcetateInterlude Biopharma Co. · Phase 3
- FB102Forte Biosciences, Inc. · Phase 2
- DONQ52Roche · Phase 2
- AmlitelimabSanofi · Phase 2
- TEV-53408Teva Branded Pharmaceutical Products R&D LLC · Phase 2
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Aug 2027 | Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease | |
| Phase 2Completed | 7 Jun 2023 | Different Doses of ZED1227 vs. Placebo in NAFLD | |
| Phase 1Completed | 19 Jun 2023 | A Study of TAK-227 in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026